NO20004816D0 - New pharmaceutical formulation - Google Patents

New pharmaceutical formulation

Info

Publication number
NO20004816D0
NO20004816D0 NO20004816A NO20004816A NO20004816D0 NO 20004816 D0 NO20004816 D0 NO 20004816D0 NO 20004816 A NO20004816 A NO 20004816A NO 20004816 A NO20004816 A NO 20004816A NO 20004816 D0 NO20004816 D0 NO 20004816D0
Authority
NO
Norway
Prior art keywords
pharmaceutical formulation
new pharmaceutical
new
formulation
pharmaceutical
Prior art date
Application number
NO20004816A
Other languages
Norwegian (no)
Other versions
NO20004816L (en
Inventor
Marianne Eklund
Jan-Erik Loefroth
Mats Sundgren
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20004816D0 publication Critical patent/NO20004816D0/en
Publication of NO20004816L publication Critical patent/NO20004816L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20004816A 1999-07-20 2000-09-26 New pharmaceutical formulation NO20004816L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902742A SE9902742D0 (en) 1999-07-20 1999-07-20 New pharmaceutical formultion
PCT/SE1999/002474 WO2001005376A1 (en) 1999-07-20 1999-12-22 New pharmaceutical formulation

Publications (2)

Publication Number Publication Date
NO20004816D0 true NO20004816D0 (en) 2000-09-26
NO20004816L NO20004816L (en) 2000-11-02

Family

ID=20416534

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004816A NO20004816L (en) 1999-07-20 2000-09-26 New pharmaceutical formulation

Country Status (9)

Country Link
EP (1) EP1113786A1 (en)
JP (1) JP2003504392A (en)
KR (1) KR20010078703A (en)
CN (1) CN1319004A (en)
AU (1) AU3095600A (en)
CA (1) CA2328102A1 (en)
NO (1) NO20004816L (en)
SE (1) SE9902742D0 (en)
WO (1) WO2001005376A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211149A1 (en) * 2002-05-07 2003-11-13 Sherman Bernard Charles Extended release tablets comprising felodipine
GB0222612D0 (en) * 2002-09-30 2002-11-06 Univ Gent Controlled delivery system for bioactive substances
ATE411817T1 (en) * 2004-11-17 2008-11-15 Ares Trading Sa BENZOTHIAZOLE FORMULATIONS AND THEIR USE
CN101103964B (en) * 2006-07-14 2010-09-29 海南盛科生命科学研究院 A kind of sustained-release preparation containing felodipine and preparation method thereof
KR100841877B1 (en) * 2006-08-31 2008-06-27 조선대학교산학협력단 Controlled-release formulations of topically solubilized poorly soluble drugs and methods for preparing the same
CN102784128B (en) * 2012-07-31 2015-01-07 北京协和药厂 Felodipine sustained release preparation and preparation method of felodipine sustained release preparation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601624D0 (en) * 1986-04-11 1986-04-11 Haessle Ab NEW PHARMACEUTICAL PREPARATIONS
DE3738236A1 (en) * 1987-11-11 1989-05-24 Euro Celtique Sa BIT CAPSULE
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
WO1999021534A1 (en) * 1997-10-27 1999-05-06 Merck Patent Gmbh Solid state solutions and dispersions of poorly water soluble drugs

Also Published As

Publication number Publication date
CA2328102A1 (en) 2001-01-20
CN1319004A (en) 2001-10-24
KR20010078703A (en) 2001-08-21
NO20004816L (en) 2000-11-02
AU3095600A (en) 2001-02-05
SE9902742D0 (en) 1999-07-20
WO2001005376A1 (en) 2001-01-25
EP1113786A1 (en) 2001-07-11
JP2003504392A (en) 2003-02-04

Similar Documents

Publication Publication Date Title
FIU20000164U0 (en) New pharmaceutical formulation
NO20012915D0 (en) New pharmaceutical formulation
FI991485A0 (en) New pharmaceutical composition
ITTO20010008A0 (en) PHARMACEUTICAL FORMULATION
NO992339D0 (en) Pharmaceutical Formulations
NO20015175L (en) Pharmaceutical composition
ID24654A (en) OMEPRAZOLA PHARMACEUTICAL FORMULATION
NO20033384L (en) Pharmaceutical Formulation
NO20025450L (en) New pharmaceutical composition
DK1189853T3 (en) concrete Formulation
PT1242087E (en) PHARMACEUTICAL COMPOSITIONS
NO20033785L (en) Pharmaceutical formulation
NO20020086D0 (en) Flavor-masked pharmaceutical liquid formulations
NO20015670L (en) Improved pharmaceutical formulations
NO20035627D0 (en) Pharmaceutical formulation
NO20022606D0 (en) Pharmaceutical combinations
PT1239832E (en) PHARMACEUTICAL COMPOSITIONS
ID30032A (en) PHARMACEUTICAL FORMULATION
AR025867A1 (en) PHARMACEUTICAL PORTASDORA FORMULATION
FI4488U1 (en) Pharmaceutical composition
NO20015104D0 (en) New pharmaceutical preparation
EE200100697A (en) Pharmaceutical complex
SE9803952D0 (en) Pharmaceutical formulation
SE9902902D0 (en) New formulation
NO20041236L (en) Pharmaceutical Formulation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application